
|Videos|October 7, 2017
CD101: A New Long-Acting Echinocandin
Author(s)Contagion® Editorial Staff
David Andes, MD, shares the half-life and dosing intervals for a new long-acting echinocandin.
Advertisement
David Andes, MD, professor and chief of infectious disease at the University of Wisconsin, shares the half-life and dosing intervals for a new long-acting echinocandin.
Advertisement
Advertisement
Advertisement
Trending on Contagion Live
1
Invivyd doses first participants in phase 3 COVID-19 trial of VYD2311
2
ASM Initiative Aims to Advance Phage Therapy for Drug-Resistant Infections
3
The HIV Testing Gap and What Clinicians Can Do About It
4
When Fever in Infants is Invasive Bacterial Infection
5







































































































































































